BLUE News and Press, bluebird bio Inc. From 05/05/21

bluebird bio (BLUE): Q1 GAAP EPS of -$3.07 misses by $0.08.Revenue of $12.79M (-41.5% Y/Y) beats by $1.17M.Press Release For further details see: bluebird bio EPS misses by $0.08, beats on revenue

bluebird bio, Inc. (NASDAQ: BLUE) today reported financial results and business highlights for the first quarter ended March 31, 2021 and shared recent operational progress. “Undoubtedly the highlight of last quarter at bluebird was the approval of Abecma, the first and only ...

bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: BofA Securities 2021 Health Care Conference, Thursday, May 13, at 9:30 am ET 2021 RBC Capital Markets Global Healthcare Confer...

Bristol Myers Squibb (NYSE: BMY) and bluebird bio (NASDAQ: BLUE) recently gained Food and Drug Administration approval of Abecma. In this video from Motley Fool Live , recorded on Mar ch 2 9 , Fool.com Contributors Brian Orelli and Keith Speights disc...

Last week, Vertex Pharmaceuticals (NASDAQ: VRTX) announced that it would pay CRISPR Therapeutics (NASDAQ: CRSP) a whopping $900 million to take more control of the duo's gene therapy collaboration, CTX001. CTX001 is being investigated as a potentially curative treatment for ...

In the past few years, the CAR-T, gene-based, regenerative medicines sector is becoming prominent. The premier logistic provider, Cryoport, is leading at the forefront of this innovation. When I first made my recommendation back in January 2018, Cryoport was trading at only $6.97....

The decision by bluebird bio ([[BLUE]] +0.1%) to withdraw Zynteglo (betibeglogene autotemcel) for transfusion-dependent β-thalassemia (“TDT”) from the German market did not come as a surprise.A Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid le...

bluebird bio (BLUE) has decided to withdraw Zynteglo (betibeglogene autotemcel) for transfusion-dependent β-thalassemia ("TDT") from the German market due to unsuccessful reimbursement negotiations.bluebird says the price offered by German authorities didn't reflect the value offe...

bluebird bio, Inc. (Nasdaq: BLUE) announced today business and program updates across its severe genetic disease portfolio including a revised diagnosis for the previously reported case of myelodysplastic syndrome (MDS) in its Phase 1/2 study of LentiGlobin for sickle cell disea...

bluebird bio (NASDAQ: BLUE) ran into some issues with manufacturing its gene therapy, and then the drugmaker was sideswiped by the possibility that its treatment might cause cancer. In this video from Motley Fool Live , recorded on Mar ch 22 , Fool.com contributo...